Latest Oncology News

CDK9 Inhibitor GFH009 Advances in Phase 1 Trial in Relapsed/Refractory Lymphoma and AML

CDK9 Inhibitor GFH009 Advances in Phase 1 Trial in Relapsed/Refractory Lymphoma and AML

June 28th 2022

Caroline Seymour

The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia and lymphoma.

Investigators Explore RARA Overexpression With Tamibarotene in Higher-Risk MDS

Investigators Explore RARA Overexpression With Tamibarotene in Higher-Risk MDS

June 28th 2022

OncLive Staff

Risk stratification for patients with myelodysplastic syndrome have afforded those with asymptomatic or low-risk disease treatment pathways that can be navigated using a variety of patient characteristics. However, treatment algorithms for patients with higher-risk disease are limited to allogeneic transplant or treatment with hypomethylating agents.

Penile Cancer Is Treatable, But the Armamentarium is Thin

Penile Cancer Is Treatable, But the Armamentarium is Thin

June 28th 2022

Jason Harris

Among men in the United States, incidence-based mortality is growing for penile cancer even though incidence remained consistent from 2000 to 2018.

HER-Vaxx Plus Chemotherapy Improves OS in HER2+ Advanced Gastric/GEJ Cancer

HER-Vaxx Plus Chemotherapy Improves OS in HER2+ Advanced Gastric/GEJ Cancer

June 28th 2022

Caroline Seymour

The addition of the HER2-Vaxx vaccine to standard-of-care chemotherapy led to a significant improvement in overall survival vs SOC chemotherapy alone in patients with HER2-neu overexpressing advanced and metastatic gastric and gastroesophageal junction cancer.

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

June 28th 2022

Chris Ryan

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.

Latest Oncology Videos

All Oncology News

Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma

June 28th 2022

Ashling Wahner

Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.

Florida Cancer Specialists & Research Institute Welcomes Medical Oncologist Richard McDonough, MD

June 28th 2022

Florida Cancer Specialists

Florida Cancer Specialists & Research Institute welcomes Board-certified medical oncologist Richard McDonough, MD to the statewide practice.

Obe-cel CAR T-cell Therapy Demonstrates Promising Safety Profile in Relapsed/Refractory B- ALL

June 28th 2022

Ashling Wahner

Daniel DeAngelo MD, PhD, discusses the data seen with obecabtagene autoleucel as a novel treatment in the CAR T-cell arena, emphasizes unmet needs in B-cell acute lymphoblastic leukemia, and highlights important next steps in the study of obe-cel.

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

June 27th 2022

Kristi Rosa

The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

June 27th 2022

Caroline Seymour

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk, early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

OncLive Staff

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Japanese Regulatory Approval Sought for Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer

June 27th 2022

Jason Harris

A supplemental New Drug Application has been submitted to Japan’s Ministry of Health, Labour, and Welfare seeking approval for use of trastuzumab deruxtecan for the treatment of adult patients with HER2-low unresectable or recurrent metastatic breast cancer following chemotherapy

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

June 27th 2022

Hope S. Rugo, MD

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

Sylvester Researchers Uncover New Cellular Oxygen-Sensing Pathway

June 27th 2022

Sylvester Comprehensive Cancer Center

A team of researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has identified a new cellular oxygen-sensing pathway – a discovery that could potentially lead to new approaches for treating cancer and other diseases.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

June 27th 2022

Andrew D. Seidman, MD

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

June 27th 2022

John Heymach, MD, PhD

Expert oncologist John Heymach, MD, PhD, addresses the potential role of immunotherapy in concomitant KRAS/TP53-mutated NSCLC.

TX05 Provides Comparable DFS Benefit to Trastuzumab in Early-Stage HER2+ Breast Cancer

June 27th 2022

Chris Ryan

Adjuvant treatment with TX05 resulted in a similar disease-free survival benefit to that of trastuzumab in patients with early-stage HER2-positive breast cancer.

Institutional Perspectives in Cancer- Lung: Chaired by Giuseppe Lo Russo, MD, PhD

June 27th 2022

Institutional Perspectives in Cancer- Lung: Chaired by Giuseppe Lo Russo, MD, PhD

See All News